News

Apr 03 2018

The recent FDA clearance for Auris Health, formerly known as Auris Surgical Robotics, brings to light the immense opportunity for the surgical robotics market as it continues to grow. According to the article, the competition is growing, and the global surgical robotics market could reach $12.6 billion by 2025. The article also highlights the importance of collaboration between the robotics companies and hospitals to allow for full adoption of surgical robots.

Apr 03 2018

Since Auris has received FDA clearance for its Monarch Platform, the innovative robotic technology is catching the attention of many in the healthcare and robotics space. The Monarch Platform was featured in an article by Surgical Products Magazine. According to the article, the Monarch Platform’s approach to flexible technology with its application in bronchoscopy could be a game-changer. The article explains why Auris Health CEO, Dr. Frederic Moll, believes the technology has the potential to transform the treatment of lung cancer. It also explains how Dr. Moll’s guidance has shaped the direction of Auris, including the acquisition of Hansen Medical’s technology.

Mar 29 2018

Auris’s Monarch Platform was featured in MedGadget, an online publication that covers the latest news in medical technology around the world, in an article titled “Monarch Robotic Endoscopy for Spotting Small, Deep-Seated Lung Nodules Cleared by FDA.”

Mar 26 2018

Business Insider featured Auris’s Monarch Platform, including an animation of what happens during a bronchoscopy procedure. The article also notes that the Monarch Platform integrates the latest advancements in robotics, software, data science, and endoscope innovation, saying “Auris’s newest platform, called Monarch, is designed with the intent of transforming endoscopy, particularly in the field of lung cancer diagnosis.”

Mar 25 2018

Auris is featured in this TechCrunch article, titled “Monarch is a new platform from surgical robot pioneer Frederic Moll,” for the reveal of its robotic endoscopic technology called the Monarch Platform. With the use of the Monarch Platform’s flexible robotics and controller, a physician can navigate to hard-to-reach places in the periphery of the lung. Auris’s goal is to help clinicians diagnose and treat lung cancer in the early stages, because the prognosis for lung cancer is worse for the patient if it is discovered at an advanced stage.

Mar 23 2018

Auris Health's Monarch Platform has been cleared by the FDA. The company's Chief Strategy Officer, Josh DeFonzo, summarizes some of the key features and benefits of the new technology, aimed to improve the current bronchoscopy procedure.

Mar 23 2018

Operated by a hand-held controller, Auris Health’s recently FDA-cleared Monarch Platform has lung cancer as its first targeted disease state. According to the article, the FDA determined the technology Auris built was equivalent to other bronchoscopic procedures that use endoscopy to examine a patient’s lungs. However, with the integration of the latest advancements in robotics, software, data science, and endoscope innovation, Auris aims to go further than conventional endoscopy.

Mar 23 2018

Fred Moll’s Auris Health has been granted FDA clearance for its surgical robotics platform. The nod clears the Intuitive Surgical founder’s latest venture to sell the device for use in bronchoscopic diagnostic and therapeutic procedures in lung cancer patients.

Jan 19 2018

Auris Health, formerly known as Auris Surgical Robotics, made its way to the top for most venture capital funding in the medical device industry in 2017, marking an exciting time not only for Auris but for the industry overall last year.

Jan 10 2018

Auris Health, formerly known as Auris Surgical Robotics, finds itself in good company with other billion-dollar valuation startups, all working to revolutionize healthcare in 2018.